Evidence map›Paper›PMID 40520789›Full record

ArticleFrontiers in medicine2025

Clinical characteristics of patients with pulmonary sarcoidosis treated with systemic steroids in Japan.

Michiru Sawahata, Hirokazu Kimura, Takeshi Hattori, Tsutomu Tamada, Masashi Bando, Makoto Maemondo, Takeshi Kawanobe, Chiyoko Kono, Tetsuo Yamaguchi, Noriharu Shijubo and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. New Therapies for Sarcoidosis: Molecular and Pathophysiological Basis.International journal of molecular sciences · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Michiru Sawahata *Division of Pulmonary Medicine, Department of Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan.
Hirokazu Kimura *Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan.
Takeshi HattoriDepartment of Respiratory Medicine, National Hospital Organization Hokkaido Medical Center, Sapporo, Hokkaido, Japan.
Tsutomu TamadaDepartment of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
Masashi BandoDivision of Pulmonary Medicine, Department of Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan.
Makoto MaemondoDivision of Pulmonary Medicine, Department of Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan.
Takeshi KawanobeDepartment of Respiratory Medicine, JR Tokyo General Hospital, Shibuya, Tokyo, Japan.
Chiyoko KonoDepartment of Respiratory Medicine, JR Tokyo General Hospital, Shibuya, Tokyo, Japan.
Tetsuo YamaguchiDepartment of Respiratory Medicine, Shinjuku Tsurukame Clinic, Shibuya, Tokyo, Japan.
Noriharu ShijuboDepartment of Respiratory Medicine, JR Sapporo Hospital, Sapporo, Hokkaido, Japan.
Takafumi SudaSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
Satoshi KonnoDepartment of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Severe pulmonary sarcoidosis is less common in Japan than in other countries, and the actual clinical situation of systemic steroid use in Japan requires clarification. Methods: This study analyzed 65 patients with histologically diagnosed sarcoidosis who initially received systemic steroids for pulmonary lesions and made regular outpatient visits to Hokkaido University Hospital, JR Sapporo Hospital, or JR Tokyo General Hospital in September 2017. Results: Median age at diagnosis was 35 (interquartile range [IQR] 26-48) years. Thirty-four patients (52.3%) were men. Median time from diagnosis to steroid initiation was 5 (IQR, 1-9) years. Median maximum steroid dose was prednisolone (PSL) 30 (range 5-60) mg/day. Immunosuppressants were used in 19 patients (29.2%). Twenty-one patients (32.3%) received PSL ≤ 10 mg/day and 7 (10.8%) received 5 mg/day. The PSL ≤ 10 mg/day group included a significantly lower proportion of men than the group treated with higher doses (33.3% vs. 61.4%, Conclusion: Approximately one-third of patients received an initial steroid dose of PSL ≤ 10 mg/day for pulmonary sarcoidosis. This was mostly effective and the withdrawal rate was relatively high. Our results support that some Japanese patients with pulmonary sarcoidosis may successfully receive an initial dose of PSL ≤ 10 mg/day.

Indexed as

guidelineimmunosuppressantsarcoidosissteroidtreatment

Identifiers

PMID40520789
PMCPMC12162477

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.